Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
Date:2/21/2012

t, Mylan will host an investor meeting in New York City.   The presentations will be broadcast live via webcast beginning at 1 p.m. ET and are expected to conclude at 5 p.m. ET. A replay will be available for 30 days on Mylan's website after the event's conclusion. If you are unable to access the live webcast, you can participate in listen-only mode at 877.567.9753.

To access the live webcast and view the accompanying slide presentations, visit the Investor Relations section of Mylan's website, at http://investor.mylan.com, at least 15 minutes before the presentation is scheduled to begin; click on the webcast icon to register and download or install any necessary software.  

About MylanMylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

Forward Looking StatementsThis press release includes statements that constitute "forward-looking statements", including with regard to the Company's future operations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such d
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
2. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
3. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
4. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
5. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
6. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
7. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
8. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
9. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
10. Mylan Launches First Generic Version of Teveten® Tablets
11. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer ... protective stent system, today announced another positive study, reinforcing MGuard,s ... evaluation by Drs. Dmitry Dratva, Yaron Almagor, Jonathan Balkin, David ... Department of Cardiology at Shaare Zedek Medical ...
... SpeechTrans, a leader in app-based multi-language translation, ... Impaired. The new app enables the hearing impaired to ... Italian and German and Mandarin Chinese without the need ... With the new app, each person can simply speak ...
Cached Medicine Technology:Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 2Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 3Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 4Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 5Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 6SpeechTrans Offers Mobile Translation App for Hearing Impaired 2
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... initiate a range of care management programs for people living ... room (ER) use, improved health and lower costs. The ... (ACHP), are part of a report that is a comprehensive ... to improve care. Care management is the coordination ...
... Factors for,Developing MS, UB Study Shows, Summary: ... (CCSVI), which has attracted global attention as possibly being correlated ... the presence of risk factors in subjects who do not ... of 252 volunteers has found an association between CCSVI and ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... fiddling with food and drink or doing some last-minute grooming, ... admit to being dangerously distracted while behind the wheel, a ... Interactive/HealthDay poll, most adults who drive on a regular ...
... or respirators put health care workers at risk of 2009 ... in the U.S., according to a study published in the ... the journal of the Society of Healthcare Epidemiology of America. ... Disease Control and Prevention (CDC), tracked 63 Southern California health ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women with lobular ... other forms of breast cancer to have a father who ... Swedish researchers examined the family history, pathology reports and hospital ... 2008. About 40 percent of the women had invasive ductal ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- About 40 percent ... before high school, which suggests that suicidal thoughts and behavior ... new study. As part of an ongoing survey, University ... or 19, about their history of suicide attempts. Nearly ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
... & Lomb PMMA Anterior Chamber Intraocular Lenses ... aphakia in patients 60 years of age ... been removed by primary intracapsular cataract extraction; ... is a structural reason that the anterior ...
... STAARVISC II is a sterile nonpyrogenic, transparent ... STAARVISC II contains 12 mg/ml of high ... sodium hyaluronate dissolved in physiological saline. In ... viscosity is 105,000 cps (105 Pa s) ...
... Methylcellulose solution that is especially well suited ... incision surgery. The low molecular weight of ... minimal risk of elevated intraocular pressure. The ... of the surgical field throughout capsulorhexis and ...
... AMO Vitrax features a low ... protection and viscosity you need ... phaco and small-incision surgery. The ... anterior chamber depth for safe, ...
Medicine Products: